Reactive Lymph Nodes Do Not Upstage Ovarian Carcinoma
If the right and left lymph nodes are reactive (non-metastatic), they do NOT affect the FIGO staging of ovarian carcinoma. The stage depends entirely on the extent of tumor involvement in other sites, not on reactive lymph node changes.
Key Staging Principle
According to the FIGO staging system, only cytologically or histologically confirmed metastasis to retroperitoneal lymph nodes upstages disease to Stage III 1. Reactive lymph nodes represent benign inflammatory changes without malignant cells and therefore have no staging implications.
Understanding the FIGO Staging Framework
The staging of ovarian carcinoma with regard to lymph nodes works as follows:
Stage I-II disease: Tumor confined to ovaries/fallopian tubes (Stage I) or with pelvic extension (Stage II), without lymph node metastases 1
Stage IIIA1: Disease is upstaged to Stage III only when retroperitoneal lymph nodes contain cytologically or histologically proven metastases 1:
- IIIA1(i): Metastasis ≤10 mm in greatest dimension
- IIIA1(ii): Metastasis >10 mm in greatest dimension
Higher stages (IIIA2-IV): Involve peritoneal spread or distant metastases beyond lymph nodes
Clinical Implications
Reactive lymph nodes are a common finding and should not be confused with metastatic involvement. The distinction is critical:
- Reactive nodes show benign hyperplasia in response to inflammation or immune stimulation
- Metastatic nodes contain malignant epithelial cells confirmed by pathology
- Without histologic/cytologic proof of malignancy, lymph nodes cannot upstage disease 1
Common Pitfall to Avoid
Do not upstage based on imaging findings of enlarged lymph nodes alone. The FIGO system explicitly requires cytological or histological confirmation of lymph node metastases 1. Enlarged reactive nodes on CT or PET-CT without pathologic confirmation do not constitute Stage III disease.
Determining the Actual Stage
To determine the correct FIGO stage when lymph nodes are reactive, assess:
- Tumor location: Confined to ovaries/tubes (Stage I) vs. pelvic extension (Stage II)
- Capsule integrity: Intact vs. ruptured (affects IC substaging)
- Peritoneal involvement: Presence of extra-pelvic peritoneal disease (Stage III)
- Distant metastases: Pleural effusion with positive cytology (IVA) or parenchymal/extra-abdominal metastases (IVB)
The stage is determined by the most advanced site of disease involvement, independent of reactive lymph node status.